Pharming Group N.V.
Pharming Group N.V. is a Dutch biopharmaceutical company focused on medicines for rare, debilitating, and life-threatening diseases. Its business combines the development and commercialization of small-molecule and biologic therapies through operations in Europe and the United States.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueApproved therapies sold to patients with rare immune and inflammatory diseases.
Protein-based medicines developed and commercialized for specialty indications.
Oral or chemically synthesized medicines used in rare-disease treatment.
Research and clinical programs intended to expand the rare-disease portfolio.
Customers
Pharming sells into the rare-disease treatment ecosystem, where demand is driven by specialist physicians, hospitals, and treatment centers managing complex genetic or immunological disorders. Patients ultimately receive the therapies through healthcare providers and reimbursing payers, so access and diagnosis are important commercial drivers. The company also depends on healthcare systems and pharmacies that support specialty-drug distribution.
Prescribe RUCONEST® and Joenja® for rare-disease patients based on diagnosis and clinical need.
Administer or coordinate specialty therapies for severe, medically complex cases.
Approve reimbursement and influence access to high-cost orphan medicines.
Distribute the medicines to patients and support fulfillment of prescriptions.
Strategy
Pharming’s strategy centers on building and commercializing a portfolio of rare-disease medicines, with a focus on expanding use of RUCONEST® and Joenja® and broadening its therapeutic reach. The business also relies on maintaining regulatory, clinical, and commercial execution in multiple markets, where patient identification and reimbursement are key to growth. Portfolio expansion through biologics and small molecules supports longer-term diversification beyond a single product.
Commercial medicines are the core revenue engine and support scale in specialty markets.
Diversification reduces reliance on any one therapy and extends the company’s addressable market.
Rare-disease products depend on reimbursement, diagnosis, and specialist adoption in each country.
Geography
Pharming is headquartered in Leiden, the Netherlands, and operates across the United States and Europe. The company’s commercial footprint is international, with the U.S. an important market for approved rare-disease medicines and Europe supporting both commercial and corporate operations. Because its products are specialty therapies, access, reimbursement, and regulatory approvals vary by country and can shape market opportunity.
Risks
Pharming’s business is exposed to clinical, regulatory, and commercial risks typical of rare-disease drug developers, including trial outcomes, market access, and competitive therapies. Because revenues depend on a small number of specialty products, adoption, reimbursement, and physician diagnosis rates can materially affect performance. The company also faces execution risk in commercialization and the ongoing need to support its development pipeline.
- Market access and reimbursement riskImpact: HighLikelihood: High
Specialty medicines require payer coverage and country-level reimbursement decisions.
Exposure: RUCONEST® and Joenja® commercialization
- Product concentration riskImpact: HighLikelihood: High
Revenue depends on a limited number of therapies in narrow patient populations.
Exposure: Commercial rare-disease portfolio
- Clinical development riskImpact: HighLikelihood: Medium
Pipeline programs depend on successful trial design, enrollment, and data outcomes.
Exposure: Rare-disease pipeline and new indications
- Regulatory riskImpact: MediumLikelihood: Medium
Approvals, label changes, and post-marketing obligations can affect sales and development timelines.
Exposure: U.S. and European operations
Accounting
Judgemental itemsSpecialty-drug sales can involve gross-to-net deductions and timing differences between shipment and net revenue.
Impact: Affects reported revenue and margins
Payer rebates, discounts, and product returns can materially change net sales in rare-disease markets.
Impact: Affects net revenue and receivables
Drug programs may create capitalized assets whose value depends on future commercialization success.
Impact: Affects amortization and impairment risk
Management must assess funding for at least the next twelve months in interim reporting.
Impact: Affects disclosure and liquidity analysis
Similar listed companies
Publicly listed companies with a comparable business focus.
Pharvaris N.V.
PHVS · Pharmaceutical Preparations
Fulcrum Therapeutics, Inc.
FULC · Pharmaceutical Preparations
Mereo BioPharma Group plc
MREO · Pharmaceutical Preparations
Mereo BioPharma Group plc is a biopharmaceutical company focused on developing late-stage therapies for rare diseases.
Eton Pharmaceuticals, Inc.
ETON · Pharmaceutical Preparations
argenx SE
ARGX · Biological Products, (No Diagnostic Substances)
argenx SE is a Dutch biopharmaceutical company focused on discovering and commercializing antibody-based medicines for severe autoimmune diseases.
Ionis Pharmaceuticals, Inc
IONS · Pharmaceutical Preparations
Ionis Pharmaceuticals is a U.S.-based biotechnology company focused on RNA-targeted medicines, using antisense chemistry to discover and develop therapies for serious diseases.
Last updated: 28/09/2026